Compared to the Combivir and Sustiva regimen, in which 73 percent of patients responded, the newer triple combination suppressed the AIDS virus in 84 percent of patients, with fewer side effects and more potent immune effects. The findings were recently published in the New England Journal of Medicine.
"The superior outcome," the study authors write, "provides further support for the use of this regimen in patients who have not previously received antiretroviral therapy." Government guidelines list Viread and Truvada among the "preferred" regimens for people who have not been previously treated for HIV.
In a statement, Gilead, the company that makes Truvada, said they plan to submit a new drug application to the FDA for combining Truvada and Sustiva. If accepted, patients could soon have the option of taking only one pill a day to control HIV, down from the 12 to 24 pills once needed.